4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Assets Average of $539.8 million for Q1 2026, little changed year-over-year from $538.1 million in Q1 2025, and up 8.98% quarter-over-quarter from $495.3 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Assets Average for 6 consecutive years, with $539.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average changed 0.33% year-over-year to $539.8 million; the TTM figure through Mar 2026 stood at $539.8 million (changed 0.33% YoY), while the FY2025 annual figure was $563.5 million, up 25.19% from the prior year.
- Assets Average advanced to $539.8 million in Q1 2026 per FDMT's latest filing, from $495.3 million in the prior quarter.
- Across five years, Assets Average topped out at $625.0 million in Q2 2024 and bottomed at $252.9 million in Q1 2023.
- Historically, Assets Average has averaged $429.2 million across 5 years, with a median of $448.8 million in 2025.
- Annual changes were most pronounced in 2024 — Assets Average soared 109.55% — and 2025, when it fell 26.67%.
- 4D Molecular Therapeutics' Assets Average stood at $271.0 million in 2022, then climbed by 29.43% to $350.8 million in 2023, then surged by 65.99% to $582.2 million in 2024, then fell by 14.92% to $495.3 million in 2025, then advanced by 8.98% to $539.8 million in 2026.
- Business Quant data shows FDMT's Assets Average at $539.8 million in Q1 2026, $495.3 million in Q4 2025, and $448.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 502.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 502.76 Mn |
| Mar 31, 2026 | 539.81 Mn |
| Dec 31, 2025 | 495.35 Mn |
| Sep 30, 2025 | 448.81 Mn |
| Jun 30, 2025 | 494.68 Mn |
| Mar 31, 2025 | 538.06 Mn |
| Dec 31, 2024 | 582.21 Mn |
| Sep 30, 2024 | 612.07 Mn |
| Jun 30, 2024 | 625.00 Mn |
| Mar 31, 2024 | 484.89 Mn |
| Dec 31, 2023 | 350.75 Mn |
| Sep 30, 2023 | 357.06 Mn |
| Jun 30, 2023 | 298.26 Mn |
| Mar 31, 2023 | 252.93 Mn |
| Dec 31, 2022 | 271.01 Mn |
| Sep 30, 2022 | 291.55 Mn |
| Jun 30, 2022 | 313.93 Mn |
| Mar 31, 2022 | 339.21 Mn |
| Dec 31, 2021 | 297.05 Mn |
| Sep 30, 2021 | 247.78 Mn |